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Abstract
Human chorionic gonadotropin (hCG) contains five acidic N-linked sugar chains, which are derived from three neutral
oligosaccharides by sialylation. Each of the two subunits (hCGK and hCGL) of hCG contain two glycosylated Asn residues.
Glycopeptides, each containing a single glycosylated Asn, were obtained by digestion of hCGK with trypsin, and of hCGL
with chymotrypsin and lysyl endopeptidase. Comparative study of the sugar chains of the four glycopeptides revealed the
occurrence of site-directed glycosylation. Studies of the sugar chains of hCGs, purified from urine of patients with various
trophoblastic diseases, revealed that choriocarcinoma hCGs contain sialylated or non-sialylated forms of eight neutral
oligosaccharides. In contrast, hCGs from invasive mole patients contain sialyl derivatives of five neutral oligosaccharides.
The structural characteristics of the five neutral oligosaccharides, detected in choriocarcinoma hCGs but not in normal
placental hCGs, indicate that N-acetylglucosaminyltransferase IV (GnT-IV) is abnormally expressed in the malignant cells.
This supposition was confirmed by molecular biological study of GnT-IV in placenta and choriocarcinoma cell lines. The
appearance of tumor-specific sugar chains in hCG has been used to develop a diagnostic method of searching for malignant
trophoblastic diseases. In addition, a summary of the current knowledge concerning the functional role of N-linked sugar
chains in the expression of the hormonal activity of hCG has been presented. ß 1999 Elsevier Science B.V. All rights
reserved.
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1. Introduction
Human chorionic gonadotropin (hCG) is a glyco-
protein hormone, which is produced by the syncytio-
trophoblast cells of human placenta, and is involved
in the maintenance of the corpus luteum in early
pregnancy. It is a heterodimer composed of subunits
designated hCGK and hCGL. HCGK is N-glycosyl-
ated at Asn-52 and Asn-78 [1]. HCGL also contains
two N-linked sugar chains at Asn-13 and Asn-30,
and four O-linked sugar chains at Ser-121, Ser-127,
Ser-132 and Ser-138 [2].
2. N-Linked oligosaccharides of hCG
The structures of the N-linked sugar chains of
hCG were ¢rst reported in 1979 [3,4]. The establish-
ment of hydrazinolysis [5], a chemical means of re-
leasing the N-linked sugar chains from glycoproteins
as oligosaccharides, was of key importance in ena-
bling us to obtain reliable quantitative information
as to the glycosylation patterns of various glycopro-
teins. As shown in Fig. 1A, fractionation of the de-
sialylated oligosaccharide fraction obtained from the
hydrazinolysis of hCG produced three major peaks.
Structural study of the oligosaccharides in peaks I, II
and III revealed that they are N5, N6 and N8 shown
in Fig. 2, respectively [3]. At ¢rst, the data were
considered to re£ect the microheterogeneity of sugar
chains, which had been widely found in the sugar
chains of various glycoproteins. However, compara-
tive study of the sugar patterns of hCGK and hCGL
revealed that site-speci¢c glycosylation occurs in the
N-linked sugar chains of hCG. As shown in Fig.
1B,C, only N6 and N8 were detected from the
hCGK sample, while N5 and N6 were detected
from the hCGL sample, in approximately equal
amounts [6]. Using one- and two-dimensional 1H-
NMR spectroscopy, Weisshaar et al. [7] investigated
the site-speci¢c N-glycosylation of hCG. They found
that the main oligosaccharide attached to Asn-52 of
hCGK was sialylated N8. Approx. 60% of the oligo-
saccharides attached to Asn-78 of hCGK were sialyl-
ated N6 and the remainder was sialylated N8. N5
and N6, in the molar ratio of 1:3, were found to
be linked to the Asn-13 of hCGL, while mostly sialyl-
ated N5 was found to be attached to the Asn-30 of
hCGL. Amano and Kobata [8] con¢rmed their ¢nd-
ing by investigating the behaviors of four glycopep-
tides obtained from hCGK and hCGL on immobi-
lized Aleuria aurantia lectin and Concanavalin A
columns.
These data indicate that even the N8 of hCG
should not be considered an incomplete biosynthetic
product, but a ¢nal product at a particular site of the
hCG molecule.
The speci¢c distribution of di¡erent sugar chains
in the two subunits of hCG suggests that the three-
dimensional structure of the polypeptide portion of
hCG controls the maturation of the sugar moieties
linked to it. Study of the N-linked sugar chains of
the free hCGK supports this assumption. Together
with dimeric hCG, a very small amount of free
hCGK can be detected in the urine of pregnant wom-
en. In spite of having the same amino acid sequence
as the hCGK isolated from heterodimeric hCG, this
free hCGK cannot bind to hCGL [9]. Parsons and
Pierce [10] and Cole et al. [11] suggested that unusual
O-glycosylation of the free hCGK may prevent its
association with hCGL. However, Kawano et al.
[12] reported that no O-linked sugar chain was de-
tected in their free hCGK preparation. Instead, they
found that the subunit contains only one glyco-
sylated Asn, and the structures of the sugar chains
are a mixture of sialylated N5 and N6. This result
indicates that sialylated N5 on the free hCGK may
sterically inhibit association with hCGL. In due con-
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sideration of the biosynthetic mechanism of N-linked
sugar chains, these data can be interpreted as fol-
lows.
Two tetradecasaccharides (Glc3WMan9WGlcNAc2)
are added co-translationally to both hCGK and
hCGL while they are being translated in the rough
endoplasmic reticulum of syncytiotrophoblast. It was
found that the two subunits are associated before
they are transferred to the Golgi apparatus [13].
Therefore, the four N-linked sugar chains present
in the early stages of the heterodimer production
should be a series of high mannose-type sugar
chains, which will be processed to Man5WGlcNAc2
during the heterodimer’s transport to the medial
Golgi. After reaching the medial Golgi, the hetero-
dimer’s N-linked sugar chains will be processed by
the concerted action of L-N-acetylglucosaminyltrans-
ferases I and II, K-mannosidase II, L-galactosyltrans-
ferase, and sialyltransferase [14]. However, the matu-
ration of the four N-linked sugar chains is controlled
by the steric interactions of the two subunits, pro-
ducing the site-speci¢c complex-type sugar chains at
the four N-glycosylation sites. Possibly, the small
amount of free hCGK produced is a result of the
failure of the peptide to accept one tetradecasaccha-
ride in the rough endoplasmic reticulum of the syn-
cytiotrophoblast, probably because folding of the
polypeptide moiety hides one of the two potential
N-glycosylation sites of the hCGK molecule, as
found in the case of ovalbumin [15]. This hCGK
with only one N-linked sugar chain may not be
able to combine with hCGL, and is transferred to
Golgi as free hCGK. Since the maturation of its N-
linked sugar chain is not controlled by the steric
e¡ect of hCGL, it will acquire the largest complex-
type sugar chain that can be formed by the glycosyl-
ation machinery of syncytiotrophoblast.
The theory that the larger N-linked sugar chains of
free hCGK inhibit its binding with hCGL was pro-
posed by Blithe [16]. She found that a free hCGK
sample, puri¢ed from the culture medium of JEG-3
cells, contained larger complex-type sugar chains
than that dissociated from intact hCG molecules pu-
ri¢ed from the same medium. This free hCGK also
cannot combine with hCGL to form the dimeric hor-
mone. However, the free hCGK, puri¢ed from the
culture medium of JEG-3 cells grown in the presence
of swainsonine, could combine with hCGL. Virtually
all N-linked sugar chains of the free hCGK from
swainsonine-treated cells were released by endo-L-
N-acetylglucosaminidase H digestion, indicating
that they are either high mannose-type or hybrid-
type sugar chains. Therefore, it was estimated that
the complex-type sugar chains of the free hCGK
sterically inhibit its binding to hCGL. Peters et al.
[17] reported that only 10% of the free hCGK se-
creted by explants of 10 week old placenta are O-
glycosylated, and also indicated that O-glycosylation
of hCGK is a late event in the secretory pathway of
syncytiotrophoblast cells, as compared to the rapid
combination of hCG subunit precursors to form an
KL dimer in the rough endoplasmic reticulum. Based
on these data, they concluded that O-glycosylation of
the hCGK could not be the cause of production of
free hCGK.
3. HCGs in trophoblastic diseases
A large amount of hCG is detected in the sera and
the urine of patients with various trophoblastic dis-
eases [18]. The major trophoblastic diseases are a
Fig. 1. Fractionation of desialylated radioactive oligosaccharide
fractions by Bio-Gel P-4 (under 400 mesh) column. Arrows in-
dicate the elution positions of glucose oligomers (numbers indi-
cate the glucose units). (A) Oligosaccharide fraction from uri-
nary hCG obtained from a pregnant woman; (B) fraction from
hCGK of placental hCG; (C) fraction from hCGL of placental
hCG; (D) fraction from choriocarcinoma hCG.
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hydatidiform mole, an invasive mole, and choriocar-
cinoma. Hydatidiform moles are considered a benign
lesion. However, some of the hydatidiform moles
apparently show more malignant characteristics,
such as invasion into the surrounding tissues and
metastasis, and are discriminated as an invasive
mole from most typical moles. On the other hand,
patients with choriocarcinoma show de¢nitive fea-
Fig. 2. Structures of desialylated N-linked sugar chains isolated from various hCG preparations.
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tures of a malignant tumor. Although prophylactic
chemotherapy is e¡ective in retarding the develop-
ment of persistent gestational trophoblastic diseases
such as invasive mole and choriocarcinoma, use of
chemotherapy at the time of molar evacuation is
controversial because of the drug toxicity. Accord-
ingly, precise diagnosis of the patients with these
three diseases is clinically important for the treat-
ment of patients with trophoblastic diseases.
It has been known for the past three decades that
altered glycosylations occur in the glycoproteins pro-
duced by various tumor cells [19]. Because constant
N-linked sugar chain patterns were obtained from
the urinary hCGs of healthy pregnant women, it
was considered that any structural change, induced
in the sugar chains of hCG produced by choriocar-
cinoma, may be useful for developing a diagnostic
method for malignant trophoblastic diseases. An
hCG sample, puri¢ed from the urine of a patient
with choriocarcinoma, was shown to have quite a
di¡erent sugar pattern from those of normal preg-
nant women [20]. First of all, the oligosaccharide
fraction obtained by hydrazinolysis from the chorio-
carcinoma hCG was almost free from acidic oligo-
saccharides. When subjected to Bio-Gel P-4 column
chromatography, the oligosaccharide fraction gave
the elution pattern as shown in Fig. 1D. Structural
study of the oligosaccharides included in the ¢ve
peaks revealed that eight neutral oligosaccharides,
N1^N8 as shown in Fig. 2, occur in the choriocarci-
noma hCG. Further study of the sugar chains of
hCGs, puri¢ed from the urine of three additional
patients with choriocarcinoma, indicates that the de-
letion of sialic acids is not present in all choriocarci-
noma hCG [21]. However, the eight oligosaccharides,
N1^N8, were detected in all three choriocarcinoma
samples after removal of the sialic acid from the
sugar chains. The structural change detected in the
sugar chains of choriocarcinoma hCG is apparently
quite complicated, but it can be reasonably explained
by changes in two glycosyltransferases in choriocar-
cinoma. An increase in the molar ratio of total fu-
cosylated oligosaccharides (N1, N3, N5 and N7 in
Fig. 2) indicated that the fucosyltransferase respon-
sible for formation of the FucK1-6GlcNAc group is
highly expressed in choriocarcinoma cells. Appear-
ance of oligosaccharide N7 may indicate that the
fucosyltransferase has wider speci¢city than that in
normal syncytiotrophoblasts. Structurally, oligosac-
charides N1, N2, N3 and N4 can be formed by ad-
dition of the GalL1-4GlcNAcL1-4 outer chain to N5,
N6, N7 and N8, respectively. Therefore, N-acetylglu-
cosaminyltransferase IV (GnT-IV) [14] must be
strongly expressed in choriocarcinoma cells.
The N-linked sugar chains of the hCG samples,
puri¢ed from the urine of three patients with hyda-
tidiform mole, were identi¢ed as almost the same
oligosaccharide patterns as in the case of non-
trophoblastic disease hCG (Fig. 1A). However, ex-
amination of the N-linked sugar chains of urinary
hCG samples obtained from two patients with inva-
sive mole, provided additional interesting evidence as
to the mechanism of altered glycosylation of the tu-
mor hCG [22]. These samples contained the oligosac-
charides N1, N2, N5, N6, N7 and N8, but not N3
and N4. Detection of oligosaccharides N1 and N2 in
invasive mole indicated that GnT-IV is expressed in
these cells. However, absence of oligosaccharides N3
and N4 indicates that the newly expressed GnT-IV
can transfer an N-acetylglucosamine residue to bian-
tennary complex-type sugar chains, but not to mono-
antennary sugar chains. Gleeson and Schachter re-
ported that GnT-IV solubilized from Golgi
membrane can add a L-N-acetylglucosamine residue
to monoantennary sugar chains [23]. However, oligo-
saccharides N3 and N4 have not been detected in the
glycoproteins produced by various animal cells.
Hence, we called them abnormal biantennary sugar
chains expecting them to become important tumor
markers. A control mechanism to prevent formation
of abnormal biantennary sugar chains must exist in
the Golgi apparatus of normal cells.
4. Altered expression of GnT-IV in choriocarcinoma
cells
GnT-IV is expressed in many animal species [23^
27]. However, GnT-IV activities in these cells are
generally lower than other L-N-acetylglucosaminyl-
transferases (GnTs) responsible for the formation
of complex-type N-linked sugar chains. Oguri et al.
[28] recently found that high GnT-IV activity is ex-
pressed in bovine small intestine, and successfully
puri¢ed the enzyme to homogeneity. The substrate
speci¢city of this enzyme was the same as reported
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by Gleeson and Schachter [23], absolutely requiring
the presence of the GlcNAcL1-2ManK1-3 group in
the acceptor oligosaccharide. The presence of the
GlcNAcL1-2ManK1-6 or the GlcNAcL1-6ManK1-6
groups in the acceptor oligosaccharides is not essen-
tial but they are more favorable as substrates (Fig.
3). Cloning of the gene encoding this enzyme re-
vealed that the enzyme has a typical type II mem-
brane-bound protein structure, but has no homology
with other cloned GnTs [29].
In order to investigate the enzymatic basis of the
altered glycosylation of the hCG produced in chorio-
carcinoma cells, human cDNA for GnT-IV was ob-
tained from a human liver cDNA library. Surpris-
ingly, two active GnT-IV genes, with 91 and 64%
homology to the bovine GnT-IV gene, were obtained
[58]. The translation products of these two genes
were named GnT-IVa and GnT-IVb, respectively.
The cellular expression of the two genes is strikingly
di¡erent. GnT-IVb gene is expressed in all human
organs at almost the same level, while GnT-IVa
gene is highly expressed in speci¢c organs such as
pancreas, thymus, small intestine, and leukocytes
[30].
When activities of the glycosyltransferases related
to the formation of the abnormal biantennary sugar
chains were compared in normal placenta and several
choriocarcinoma cell lines, the GnT-IV activity was
strikingly increased in the cancer cells [59]. GnT-III
activity was also increased, while GnT-I and -II,
L1,4-galactosyltransferase and K-mannosidase II ac-
tivities were not increased signi¢cantly from those of
the normal placenta. They also found that GnT-II
activity in normal placenta, as well as in choriocar-
cinoma cells, was lower than in other cells which
never produce monoantennary sugar chains.
Northern blot analysis revealed that the GnT-IVa
gene was extraordinarily over-expressed in the cancer
cells, while the GnT-IVb gene was expressed at the
same level as in normal placenta [59]. So far, no
di¡erence in the substrate speci¢cities of GnT-IVa
and GnT-IVb has been found. Both can produce
the abnormal biantennary structures in vitro. The
data, so far described, indicate that low GnT-II ac-
tivity and over-expression of the GnT-IVa gene, and
the resulting increase in GnT-IV activity are the en-
zymatic basis of the formation of the abnormal bian-
tennary sugar chains in choriocarcinoma cells (Fig.
4). However, these conditions do not explain the
subtle di¡erences detected in the N-linked sugar
chains of choriocarcinoma hCG and invasive mole
hCG. Therefore, more detailed studies of the sub-
strate speci¢city of GnT-IVa, including the kinetic
parameters, and investigation of its topology in the
Golgi membrane of the cells of the two diseases must
be performed.
In view of the ¢ndings that abnormal biantennary
sugar chains occur in the glycoproteins produced by
several other tumor cells [31,32], studies searching for
abnormal biantennary sugar chains will produce im-
portant information as to the altered N-glycosylation
in malignant cells.
5. HCG as a diagnostic marker of malignant
trophoblastic diseases
As described in the previous section, qualitative
alterations are found in the N-linked sugar chains
of hCG samples puri¢ed from the urine of patients
with invasive mole and choriocarcinoma. Because
oligosaccharides N1 and N2 in Fig. 2 were detected
in invasive mole and choriocarcinoma hCGs but not
in normal pregnant hCGs and hydatidiform mole
hCGs, any method that can discriminate between
the hCG molecules with or without these oligosac-
charides could be used for the diagnosis of malignant
trophoblastic diseases.
By investigating the behavior of various complex-
type oligosaccharides on several immobilized lectin
columns, Yamashita et al. [33] found that these oli-
gosaccharides can be separated into three groups by
passing through a Datura stramonium agglutinin
(DSA)-Sepharose column. The oligosaccharides,
Fig. 3. Substrate speci¢city of GnT-IV. PA, pyridylamine. The
e¡ect of each monosaccharide residue is shown by the pattern
of the enclosing box.
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which are weakly bound to the column and eluted
with bu¡er, all contain the non-substituted GalL1-
4GlcNAcL1-4(GalL1-4GlcNAcL1-2)Man group. The
oligosaccharides, which are strongly bound and then
eluted from the column with the elution bu¡er con-
taining a 1% mixture of L-N-acetylglucosamine
oligomers, have either the GalL1-4GlcNAcL1-6-
(GalL1-4GlcNAcL1-2)Man group or the GalL1-4-
GlcNAcL1-3GalL1-4GlcNAc group as their partial
structures. The oligosaccharides having none of these
groups pass through the column without any inter-
action.
Since the binding speci¢city of the DSA-Sepharose
column was expected to be useful for discriminating
hCGs with or without oligosaccharides N1 and N2
in Fig. 2, the behavior of urinary hCGs of various
trophoblastic diseases on this column was investi-
gated [34]. Almost all hCGs in the urine of a preg-
nant woman passed through the column without in-
teraction. The elution pattern did not change even
after the urine was pretreated by sialidase digestion.
In contrast, only a portion of hCG in the urine of
a patient with choriocarcinoma passed through the
column. The remainder was not eluted even with
the elution bu¡er, but was completely recovered by
elution with 0.1 N acetic acid. This unexpectedly
strong binding might have occurred because the
hCG molecule contains at least two oligosaccharides
with the GalL1-4GlcNAcL1-4(GalL1-4GlcNAcL1-2)-
Man group. The elution step with the bu¡er contain-
ing a 1% mixture of L-N-acetylglucosamine oligo-
mers was then omitted, and the amounts of hCG
in the two fractions obtained by elution with simple
bu¡er and with 0.1 N acetic acid were measured to
determine the percentage of hCG with the GalL1-4-
GlcNAcL1-4(GalL1-4GlcNAcL1-2)Man group in
their sugar chains. As shown in Fig. 5, the values
for normal pregnant women and for patients with
hydatidiform mole were less than 15%, and did not
increase after sialidase digestion. The values for pa-
tients with invasive mole were also small, but siali-
dase treated samples showed much higher values.
Fig. 4. Deduced mechanism of the abnormal biantennary sugar chain formation in choriocarcinoma cells. In choriocarcinoma cells,
the GnT-IVa gene was much more highly expressed than in the normal placenta, which resulted in imbalance between GnT-II and
-IV enzyme activities. Bold arrow indicates the increased enzyme activity. R = GlcNAcL1-4GlcNAc-protein. GalT, L1,4-galactosyltrans-
ferase.
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The results for patients with choriocarcinoma varied
more than the others. Some of them behaved very
similar to invasive mole hCGs. However, one of the
choriocarcinoma hCGs bound completely to the col-
umn without sialidase treatment. Therefore, a⁄nity
column chromatography with use of a DSA-Sephar-
ose gel can be used e¡ectively to discriminate malig-
nant hCGs from non-malignant hCGs, obtained
from urine samples. By assigning the cuto¡ value
as 20%, desialylated hCG samples of patients with
invasive mole and choriocarcinoma can be com-
pletely discriminated from those of patients with hy-
datidiform mole and pregnant women.
6. Functional role of the sialic acid residues of hCG
Many studies revealed that modi¢cation of the N-
linked sugar chains of hCG alters its hormonal ac-
tivity [35^38]. These reports indicate that complete
removal of sialic acid residues from hCG enhances
its binding to the target cells, but reduces its hormo-
nal activity to 50%. Removal of the whole N-linked
sugar chains from hCG further increases the binding
of hCG to its target cells, but eliminates its hormonal
activity almost completely. The deglycosylated hCG
behaves as an antagonist to native hCG [39]. In an
important article, Calvo and Ryan [40] reported that
the glycopeptide mixture, obtained from hCG by ex-
haustive pronase digestion, blocks hCG signal trans-
duction and suggested that a lectin like membrane
component in addition to hCG-receptor may be in-
volved in the signal transduction. Thotakura et al.
reported that glycopeptides and oligosaccharides, ob-
tained from other glycoproteins, can also prevent the
hormonal action of hCG [41]. Matzuk et al. [42] in-
vestigated the bioactivities of hCGs, which lacked
one of the four N-linked sugar chains. They prepared
mutants of the hCG gene, in which one of the four
N-glycosylation sites was eliminated by site-directed
mutagenesis, and expressed them in Chinese hamster
ovary cells. Only the hCG sample, which lacked the
sugar chain at the Asn-52 of hCGK, signi¢cantly
decreased in vitro signal transduction.
Expression of each subunit from the gene in CHO
cells, after elimination of one of the two N-glycosyl-
ation sites by site-directed mutagenesis, revealed an-
other role of the hCG N-linked sugar chains [43]. In
hCGK, removal of Asn-78 glycosylation markedly
reduced its assembly with hCGL. Studies of hCGL
showed that the N-glycosylation is not essential for
its assembly with hCGK, but elimination of Asn-30
glycosylation inhibits the secretion of uncombined
hCGL. These results indicated that the N-linked sug-
ar chains of hCG are important for constructing the
correct conformation of each subunit.
Goverman et al. [44] reported that deglycosylation
of hCG by digestion with an exo- and endoglycosi-
dase mixture from D. pneumoniae, which leaves the
proximal N-acetylglucosamine residues of the four
N-linked sugar chains of hCG intact, does not pro-
duce any dramatic e¡ects on the folding and assem-
bly of the two subunits. Therefore, the presence of at
Fig. 5. Percent molar ratio of urinary hCGs bound to a DSA-
Sepharose column before (a) and after (b) sialidase digestion.
(A) Urine samples from normal pregnant women; (B) those
from patients with hydatidiform mole; (C) those from patients
with invasive mole; (D) those from patients with choriocarcino-
ma. Taken from [34].
Fig. 6. Schematic presentation of hCG-receptor complex. G, Gs
protein; L, lectin; R, hCG-receptor. Black circles and a triangle
indicate the sugars. Taken from [49].
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least one N-acetylglucosamine residue attached at
each of the four N-glycosylation sites are enough to
keep the correct folding of the two subunits. The role
of N-linked sugar chains in intracellular folding of
hCGL was recently investigated by Feng et al. [45].
In order to elucidate the mechanism of suppression
of hCG hormonal activity by desialylation, Amano
et al. [46] investigated the functional role of the sialic
acid residues of hCG. It was found that all sialic acid
residues of the N-linked sugar chains of hCG occur
as the Neu5AcK2-3Gal group [3]. To ¢nd out
whether this particular group is included in the func-
tional role of the sialic acid residues, the following
experiment was performed.
MA-10 cells, a mouse Leydig tumor cell line estab-
lished by Dr. Ascoli [47], produce cAMP in response
to the addition of hCG in their culture medium.
When hCG was desialylated, its hormonal activity
was reduced to approx. 50%, as in the case of the
other target cell lines. When the desialylated hCG
was resialylated by incubation with CMP-Neu5Ac
and GalL1-4GlcNAc:K2-6-sialyltransferase, the iso-
meric hCG containing the Neu5AcK2-6Gal group
gave almost the same dose-response curve as the nat-
ural hCG [46]. These results indicated that the sialic
acid residues of hCG are important for the full ex-
pression of their hormonal activity in vitro, but the
e¡ect is independent of their linkage to the galactose
residues.
Nemansky et al. [48] con¢rmed this ¢nding and
provided more important evidence. They found that
the decrease in hormonal activity caused by desial-
ylation of hCG was restored only by the addition of
a SiaK2-6 residue, but not a GalK1-3 residue, to the
galactose moiety of the GalL1-4GlcNAcL1-2ManK1-
3Man arm of the N-linked sugar chains. They also
found that further K6-sialylation of the GalL1-
4GlcNAcL1-2ManK1-6Man arm reduced the hormo-
nal activity of hCG, which indicates that the sialyl-
ation of the outer chain on the ManK1-3 arm, rather
than the ManK1-6 arm, of the N-linked sugar chains
of hCG plays an essential role in signal transduction.
They also indicated that sialylation of the O-linked
sugar chains is not important.
In order to elucidate the role of sialic acid residues
in hCG signal transduction, an N-acetylneuraminic
acid hexamer, isolated by partial sialidase digestion
of colominic acid, was added to the reaction mixture
of hCG and MA-10 cells. The oligosaccharide did
not inhibit the binding of hCG to the surface of
the target cells, but cAMP production was reduced
to 50%, when 2 mM solution of the hexasaccharide
was added [49].
These results indicate that the hexasaccharide can
only inhibit the interaction of the sialic acid residues
of hCG with the speci¢c binding site on the cell sur-
face, but did not in£uence the binding of the peptide
portion of hCG to the receptor. The possibility that
the action of the sialic acid hexamer may be due to a
non-speci¢c anionic polymer e¡ect was refuted be-
cause the addition of fucoidin did not show any in-
hibition of the [3H]hCG binding to the cell surface
receptor or cAMP production by hCG.
The presence of the sialic acid binding site on the
cell was con¢rmed using 3P-sialyllactose-conjugated
BSA as a probe [49]. Based on data indicating that
sialic acid residues bind directly to the cell surface, a
model of the hCG-receptor complex was constructed
and is shown in Fig. 6. A dual interaction of the
peptide portion and the sialylated sugar chain of
hCG with respective binding sites is essential for
the signal transduction. However, it is not clear
whether or not the lectin-like membrane component
is a part of the hormone receptor or a part of a
di¡erent molecule as shown in Fig. 6. In connection
with this, it is of interest that a region homologous to
the soybean lectin was found in the human hCG-
receptor [50].
As already discussed, hCG contains four N-linked
sugar chains. Amano and Kobata [8] studied which
of the sugar chains interact with the lectin-like com-
ponent on MA-10 cells. By investigating which sugar
chains become resistant to sialidase digestion in the
presence of MA-10 cells, they found that the sialic
acid residues linked to N5 and N8 in Fig. 2 became
resistant to sialidase digestion by binding to the tar-
get cells. However, the susceptibility of those linked
to N6 was not a¡ected by the interaction of the
hormone with the target cells. These results indicate
that the sialic acid residues of the sugar chains linked
to the Asn-52 of hCGK and the Asn-30 of hCGL
were covered when hCG bound to the target cells.
Consequently, it was concluded that one or both of
the sugar chains at these two sites should play a
critical role in signal transduction in the hormonal
action of hCG.
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7. Controversies
There are several reports which present interpreta-
tions that di¡er from those described in this review.
As introduced previously, Weisshaar et al. [7] con-
¢rmed the ¢nding that site-speci¢c distribution of the
sugar chains occurs at the four N-glycosylation sites
of hCG. However, they also found a wider distribu-
tion than that supposed by Mizuochi and Kobata 18
years ago based on the data of the sugar pattern
analyses of commercial hCGK and hCGL, which
were guaranteed more than 99% pure [6]. Further-
more, they reported that small amounts of sialylated
N9 and N10 in Fig. 2 are included as the sugar chain
linked at Asn-52 of hCGK [7]. As shown in Fig. 1A,
there are small peaks which migrated faster than
peak III. These peaks, which Mizuochi and Kobata
neglected to analyze, may contain these larger hy-
brid-type sugar chains.
Several papers have reported the presence of tri-
antennary sugar chains in normal hCG samples pu-
ri¢ed from the urine of pregnant women. However,
these samples were puri¢ed from the urine samples
collected from many pregnant women. Since trian-
tennary sugar chains occur in ample amounts on
the urinary hCGs from choriocarcinoma patients, it
cannot be ruled out that the larger sugar chains may
have originated from choriocarcinoma hCGs con-
taminating the pooled urine. Our analyses of hCG
samples puri¢ed from the urine of several healthy
pregnant women always gave the pattern as shown
in Fig. 1A. Absence of the triantennary sugar chains
is evident from the elution pattern. Furthermore, the
behavior of desialylated hCG samples from the urine
of healthy pregnant women in a DSA-Sepharose col-
umn in Fig. 5 indicates that no triantennary sugar
chains are included in these samples.
A paper, which could not be overlooked in this
regard, was published by Elliott et al. [51]. By ana-
lyzing the carbohydrate structures of hCG samples,
puri¢ed from urine of individuals with normal preg-
nancy, they also con¢rmed the occurrence of sub-
unit-speci¢c N-glycosylation, indicating that hCGK
from normal pregnancy hCG contains N6 and N8
in Fig. 2 in the percent molar ratios of 49.3 and
36.7, and normal pregnancy hCGL contains N5
and N6 in Fig. 2 as the major sugar chains. How-
ever, they also reported that hCGK contains small
amounts of N1 and N5. Since they analyzed individ-
ual samples, the problem of choriocarcinoma hCG
contamination can be ruled out. Using lectin a⁄nity
column chromatography, Skarulis et al. [52] found
that glycosylation pattern of hCG changes as gesta-
tion progresses. Therefore, detailed structural analy-
sis of the N-linked sugar chains of hCG produced at
di¡erent times in the gestation period must be per-
formed to solve this problem.
The crystal structure of hCG was reported by Lap-
thorn et al. [53]. It was indicated that only the sugar
chain at Asn-52 of hCGK is present at the interface
of the K- and L-subunits. The other three N-linked
sugar chains are located on the outer face of the
protein molecule. Purohit et al. [54] puri¢ed hCG
samples from the culture media of insect cells trans-
fected with the hCGK gene, lacking the potential N-
glycosylation at Asn-52 or Asn-78, together with the
intact hCGL gene. By studies of the circular dichro-
ism measurements and dissociation rates of the two
mutant hCGs, they concluded that the absence of
carbohydrate at Asn-52, but not at Asn-78, resulted
in conformational changes in the mutant. Based on
this evidence, they considered that the loss of hormo-
nal activity of hCG with the absence of the sugar
chain at Asn-52 was probably due to a conforma-
tional change in the heterodimer rather than to the
loss of interaction of the Asn-52 sugar chain with the
lectin on the target cells.
However, the conformational study of the sugar
chains of hCG in solution by NMR revealed that
the sugar chains at Asn-52 appear to extend into
solution [55,56]. These data support the dual recep-
tor theory. Quite recently, Thijssen-van Zuylen et al.
[57] reported that the Asn-52-linked sugar chain of
the hCG is not susceptible to digestion with peptide
N-glycosidase F, in contrast to that of free hCGK.
Therefore, more information is required for discus-
sing the actual conformation of the sugar chain of
hCG in solution.
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